Spherix revenues up in FY 10
The company has posted net loss of $7.74m, or $0.43 loss per diluted share, as compared to net loss of $9.15m, or $0.62 loss per diluted share, for
Vertex Pharmaceuticals and Genomics have agreed a four-year extension to their drug discovery partnership in a deal with a potential value exceeding $220m.
Motesanib is an investigational, orally-administered small molecule antagonist of vascular endothelial growth factor receptors 1, 2, and 3, platelet-derived growth factor receptors, and stem cell factor receptor. The